← boardnext 2027-12
NERV
Minerva Neurosciencesdistress 6/10 · elevated risk$4.45+0%today-45% from 52w high
Lead: negative symptoms in schizophrenia · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$78M
Runway
5.3 yrs
Shares 1y
+566%
Price & events
+14.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
+5.7%
1W
+2.3%
1M
-34.8%
3M
+12.1%
6M
+122.5%
1Y
+35.7%
2Y
-71.3%
5Y
-76.6%
All
Overview
- Market Cap
- $207.32M
- Volume
- 3.41K
- 52 Week Range
- $1.68 – $8.07
- Total Shares
- 46.59M
- Float Shares
- 30.87M
- Short %
- 4.28%
- % Held by Insiders
- 3.34%
- % Held by Institutions
- 97.40%
- RVOL
- 0.01x
- Beta
- -0.18
Pipeline stages · 1 programs
Roluperidone, risperidone, aripiprazole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | Roluperidone, risperidone, aripiprazole | Negative Symptoms of Schizophrenia | — | recruiting |
Catalyst news & presentations · 5
- second half of 2028Guided 55%readoutPhase 3roluperidone · Relapse assessment data after 40-week phaseSEC 8-K
- second half of 2027Guided 55%readoutPhase 3roluperidone · Topline efficacy results (PANSS Marder NSFS at 12 weeks)SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 3roluperidone · First patient screened in confirmatory Phase 3 trialSEC 8-K
- 2026-05-27fda agreementroluperidone · FDA feedback leads to extension of relapse assessment phase from 40 to 52 weeks.SEC 8-K
- 2025-10-21partnershiproluperidone · Entered into securities purchase agreement for up to $200M private placement to fund Phase 3 confirmatory trial and NDA resubmission of roluperidoneSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-15CitizensMarket Outperform
- 2026-03-12HC Wainwright & Co.Neutral
- 2025-11-06HC Wainwright & Co.Neutral
- 2025-02-26HC Wainwright & Co.Neutral
- 2024-11-06HC Wainwright & Co.Neutral
- 2024-08-07HC Wainwright & Co.Neutral
Competitors — negative symptoms in schizophrenia
- none identified
Recent news
- 2026-07-22NERV Options Chain — NASDAQ:NERV - TradingView
- 2026-07-22NERV Options Volatility — NASDAQ:NERV - TradingView
- 2026-07-17ETFs Investing in Minerva Neurosciences Inc Stocks - TradingView
- 2026-07-15FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neu - GuruFocus
- 2026-07-08Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV) - Stock Titan
- 2026-06-28Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Growth Benchmark Index - marketscreener.com
- 2026-06-28Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Value Benchmark - marketscreener.com
- 2026-06-28Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Dynamic Index - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.